These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27917557)

  • 1. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.
    Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
    Hepatol Res; 2017 Oct; 47(11):1206-1211. PubMed ID: 27917557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
    Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
    Hepatol Res; 2017 Sep; 47(10):1072-1078. PubMed ID: 27925353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
    Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
    Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.
    Miyake T; Yoshida S; Furukawa S; Sakai T; Tada F; Senba H; Yamamoto S; Koizumi Y; Yoshida O; Hirooka M; Kumagi T; Niiya T; Miyaoka H; Masanori A; Matsuura B; Hiasa Y
    Open Med (Wars); 2018; 13():402-409. PubMed ID: 30234161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
    Ishii H; Onishi Y; Oura T; Takeuchi M
    Diabetes Ther; 2020 Jan; 11(1):133-145. PubMed ID: 31758520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
    Li Y; Li L; De Peng Y; Song GY; Ye SD; Du LY; Hou JN; Ji QH
    Diabetes Ther; 2019 Aug; 10(4):1435-1452. PubMed ID: 31228090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
    Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
    Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.
    Katsuyama H; Hakoshima M; Umeyama S; Iida S; Adachi H; Yanai H
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
    Onishi Y; Ishii H; Oura T; Takeuchi M
    Diabetes Ther; 2020 Mar; 11(3):735-745. PubMed ID: 31994009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.
    Nomoto H; Takahashi Y; Takano Y; Yokoyama H; Tsuchida K; Nagai S; Miya A; Kameda H; Cho KY; Nakamura A; Atsumi T
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial).
    Sumida Y; Murotani K; Saito M; Tamasawa A; Osonoi Y; Yoneda M; Osonoi T
    Hepatol Res; 2019 Jan; 49(1):64-71. PubMed ID: 30051943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.
    Edwards KL; Minze MG
    Core Evid; 2015; 10():11-21. PubMed ID: 25657615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.
    Clements J; Moore K; Shealy K
    Expert Rev Endocrinol Metab; 2015 Nov; 10(6):581-590. PubMed ID: 30289034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study.
    Iwasaki T; Kessoku T; Higurashi T; Taguri M; Yoneda M
    Diabetol Int; 2018 Jul; 9(3):189-195. PubMed ID: 30603366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.
    Sumida Y; Seko Y; Yoneda M;
    Hepatol Res; 2017 Mar; 47(4):266-280. PubMed ID: 28019064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study.
    Seo JY; Lee CG; Choi H; Lee HK; Lee SY; Kim HJ; Jung KY; Kim JT
    Ann Pediatr Endocrinol Metab; 2023 Dec; 28(4):296-301. PubMed ID: 36758973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dulaglutide for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
    Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
    Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.